Pharvaris Reports FY 2025 Results and Anticipates CHAPTER-3 Phase 3 Topline Data in Q3 2026

Pharvaris N.V. (Nasdaq: PHVS) reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a comprehensive business update. The company ended 2025 with €291.7 million in cash and cash equivalents. A significant milestone was achieved with the completion of enrollment for CHAPTER-3, a pivotal Phase 3 study of deucrictibant extended-release (XR) for the prophylactic treatment of hereditary angioedema (HAE) attacks. Topline data from this trial is expected in the third quarter of 2026. Additionally, Pharvaris remains on track to submit a New Drug Application (NDA) for deucrictibant immediate-release (IR) for the on-demand treatment of HAE attacks in the first half of 2026, supported by positive data from the RAPIDe-3 Phase 3 study. The company is also progressing with enrollment in the CREAATE pivotal study for acquired angioedema (AAE-C1INH). Research and development expenses for 2025 were €124.5 million, reflecting increased clinical activity. The net loss for the full year 2025 was €175.7 million, or €2.97 per share.